

8 December 2023

Australian Securities Exchange
20 Bridge Street
Sydney NSW 2000

Share Purchase Plan Closure and Results

Melbourne, Victoria – Alcidion Group Limited (ASX:ALC) (“**the Company**”) refers to the Share Purchase Plan (“**SPP**”) announced on 9 November 2023.

The Company advises that the SPP closed at 5:00pm (AEDT) on Friday, 1 December 2023. Eligible shareholders subscribed for 5,039,942 fully paid ordinary shares (“**New Shares**”) under the SPP, at an issue price of \$0.075 per share, raising \$378,000.

Alcidion Group Managing Director Kate Quirke said, “We appreciate the continued support of shareholders who participated in the SPP. The SPP was undertaken to ensure all shareholders had the opportunity to participate in the capital raise on the same terms as the placement. The funds raised under the placement were sufficient to ensure Alcidion maintained a strong balance sheet, with additional funds in the SPP only further adding to that strong balance sheet position. The Company is now well capitalised as it continues to execute on the significant market opportunities ahead.”

The New Shares will be issued today, Friday 8 December 2023, and are expected to commence trading on the ASX on or about Monday 11 December 2023, with holding statements to be dispatched in due course. The New Shares will rank equally with existing ALC ordinary shares from their date of issue.

ENDS

Authorised for ASX release by Kate Quirke, Managing Director and CEO of Alcidion Group Limited.

For further information, please contact:

Hannah Howlett

WE Communications

hhowlett@we-worldwide.com

investor@alcidion.com

About Alcidion

Alcidion Group Limited (Alcidion) has a simple purpose, that is, to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations, worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver Clinical Decision Support at the point of care; all in support of Alcidion’s mission to improve patient outcomes.

Since listing on the ASX in 2011, Alcidion has acquired multiple healthcare IT companies and expanded its foothold in the UK, Australia, and New Zealand to now service over 400 hospitals and 87 healthcare organisations, with further geographical expansion planned.

With over 20 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

© Alcidion Group Limited 2023